Metabolic syndrome — the clustering of central obesity, hypertension, dyslipidemia, and insulin resistance — improves substantially on GLP-1 RA therapy. Multiple component improvements (weight, glycemia, BP, triglycerides) typically observed in trials.
Metabolic syndrome and GLP-1: No metabolic-syndrome-specific FDA indication. Use through obesity, T2D, or CV-disease indications as applicable.
The evidence
STEP-1 (sema) and SURMOUNT-1 (tirz) document multi-component cardiometabolic improvement: weight, waist circumference, A1c, fasting glucose, BP, lipids. Effects are larger than weight loss alone would predict.
FDA-approved labeling status
No metabolic-syndrome-specific FDA indication. Use through obesity, T2D, or CV-disease indications as applicable.
Practical considerations
Patients with metabolic syndrome often qualify under multiple indications simultaneously. The CV indication (Wegovy, BMI ≥27 + established CVD) may apply if CVD is documented.